EGM Statement

Fulcrum Pharma PLC
12 April 2007


                               FULCRUM PHARMA PLC
                         ('the Group' or 'the Company')
              Statement from Extraordinary General Meeting ('EGM')


Fulcrum Pharma plc (AIM:FUL), the drug development and regulatory services
company, today held its Extraordinary General Meeting at which all of the
resolutions put to shareholders were duly passed.

These resolutions enable Fulcrum to complete the acquisition of Unicus
Regulatory Services Ltd. The acquisition of Unicus is the next important step in
the delivery of Fulcrum's strategic objective to become a leader in the
provision of pharmaceutical regulatory services. Unicus strengthens Fulcrum's
existing regulatory consulting and electronic publishing services and brings new
capabilities in pharmacovigilance, product information management, regulatory
interim management, coaching & development and training. The acquisition will
enable these additional services to be provided directly to Fulcrum's clients
and expands Fulcrum's overall drug development capability.

Fulcrum's Chairman, Prof. Sir Charles George, said: 'Following our Extraordinary
General Meeting today we are pleased to report that trading continues in line
with expectations. The acquisition of Unicus is the next step towards becoming a
leading provider of pharmaceutical regulatory services in Europe. I would like
to welcome the Unicus team to Fulcrum and look forward to offering a broader and
deeper range of drug development services to our clients worldwide.'

For further information, please contact:

Fulcrum Pharma PLC
Jon Court, Chief Executive           Tel: [phone]

Seymour Pierce
Jonathan Wright                      Tel: [phone]

About Fulcrum Pharma plc

Fulcrum Pharma plc is a drug development and regulatory services business that
provides global expertise to achieve drug development and regulatory approval
milestones.

Fulcrum Pharma offers immediate access to a highly credible, integrated
development team that provides strategic and operational leadership required to
ensure that new drugs move smoothly from discovery research to product approval

Fulcrum Pharma is listed on the AIM Market of the London Stock Exchange having
successfully floated in March 2000.



                      This information is provided by RNS
            The company news service from the London Stock Exchange